Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACE-1334
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ACE-1334 (MK-2225) is a recombinant fusion protein developed as an antifibrotic agent for the treatment of systemic sclerosis (scleroderma). It is a homodimeric fragment crystallizable (Fc) fusion protein that incorporates the extracellular domain of the human transforming growth factor beta (TGF-beta) receptor, designed to act as a ligand trap. Its mechanism involves binding and inhibiting TGF-beta1 and TGF-beta3 ligands, but not TGF-beta2, thereby blocking profibrotic signaling pathways implicated in scleroderma and related fibrotic diseases. The drug was originally discovered by Acceleron Pharma and has been further developed by Merck. It has received orphan drug designation for systemic sclerosis/scleroderma. Clinical development has included phase 1 trials in healthy volunteers and patients with systemic sclerosis; some trials have been terminated due to business reasons[2][3][4][6].
- Other names
- MK-2225MK2225MK 2225ACE 1334ACE1334ACE-1334
02
Targets
TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on ACE-1334.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACE-1334.